Navigating the complexities of COVID-19

As the COVID-19 pandemic continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze.

Please note: COVID-19’s impact on pharma is continually evolving. All insights expressed here were formulated based on the situation as of May 26, 2020.

COVID-19 pharma news – tracking the fast-moving landscape

There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development.

COVID-19 treatments and vaccines (combined)

0
treatments in consideration
0
vaccines in development

When assessing possible COVID-19 treatment candidates we need to identify the relevant data to collect…

But there is no one true source of global COVID statistics

Two crucial dimensions of data quality are timeliness and accuracy – however there is no one true source of global COVID-19 statistics. We have access to multiple information streams which are often contradictory in nature.

Once we have confidence our data is relevant and accurate we need to ensure we draw meaningful conclusions

Top 12 COVID-19 treatments ranked by number of clinical trials compared to the number of patients

Licensed v experimental COVID-19 treatments – comparing the number of trials and patients

Number of patients

Number of trials

¹ Source: Biomedtracker

Where these trials are taking place around the world

Amid the rapid spread of the COVID-19 infection, companies and researchers around the world are working to develop a vaccine and effective treatments.

Get in touch with us

We’re ready and waiting to talk about how we can assist you.

This is only the beginning. Over the coming months, we will highlight the emerging patterns in the pharma industry caused by COVID-19 and crucially how this may shape the market in the future. Stay tuned for further insights.